Clarithromycin Krka: Uses, Dosage & Side Effects
A macrolide antibiotic used to treat respiratory tract infections, sinusitis, skin infections, and Helicobacter pylori eradication in duodenal ulcer disease
Clarithromycin Krka is a macrolide antibiotic containing clarithromycin as the active substance. It works by preventing bacteria that cause infections from multiplying, effectively treating a wide range of bacterial infections. Clarithromycin Krka is prescribed for adults and children aged 12 years and older for the treatment of respiratory tract infections (including bronchitis and pneumonia), throat and sinus infections, skin and soft tissue infections, and infections caused by Helicobacter pylori associated with duodenal ulcers. Available as 250 mg and 500 mg film-coated tablets, it is a well-established antibiotic included on the WHO Model List of Essential Medicines and widely used in clinical practice worldwide.
Quick Facts: Clarithromycin Krka
Key Takeaways
- Clarithromycin Krka is a macrolide antibiotic that inhibits bacterial protein synthesis, making it effective against a broad spectrum of respiratory pathogens, skin bacteria, and Helicobacter pylori.
- It is approved for adults and children aged 12 and older to treat bronchitis, pneumonia, pharyngitis, sinusitis, skin and soft tissue infections, and duodenal ulcers caused by H. pylori (in combination therapy).
- Clarithromycin has numerous critical drug interactions because it is a potent CYP3A4 inhibitor — always inform your doctor about all other medications you are taking before starting treatment.
- The standard dosage is 250 mg twice daily for 6–14 days for most infections, increased to 500 mg twice daily for severe infections or H. pylori eradication regimens.
- Complete the full prescribed course of antibiotics even if you feel better, as stopping early contributes to antibiotic resistance, a growing global health concern identified by the WHO as one of the greatest threats to public health.
What Is Clarithromycin Krka and What Is It Used For?
Clarithromycin Krka belongs to a group of antibiotics known as macrolides, which are among the most widely prescribed antibiotics worldwide. The active substance, clarithromycin, was first developed as a semi-synthetic derivative of erythromycin in the 1980s by Japanese researchers at Taisho Pharmaceutical, with the aim of improving the acid stability, oral bioavailability, and tolerability of the parent compound. It received its first regulatory approval in 1991 and has since become one of the most important antibiotics in clinical medicine, included on the World Health Organization (WHO) Model List of Essential Medicines.
Macrolide antibiotics work by inhibiting bacterial protein synthesis. Clarithromycin binds reversibly to the 50S ribosomal subunit of susceptible microorganisms, specifically at the 23S ribosomal RNA component. This binding blocks the translocation step of protein synthesis, preventing the growing peptide chain from moving from the A-site to the P-site on the ribosome. The result is that bacteria cannot produce the proteins they need to grow, repair damage, and reproduce. At standard therapeutic concentrations, clarithromycin is primarily bacteriostatic (it stops bacterial growth), although at higher concentrations or against certain particularly susceptible organisms, it can be bactericidal (it kills bacteria directly).
One of the notable pharmacological features of clarithromycin is its metabolism to an active metabolite, 14-hydroxyclarithromycin. This metabolite retains significant antibacterial activity and, for certain pathogens such as Haemophilus influenzae, works synergistically with the parent compound to provide enhanced antibacterial efficacy. This dual action contributes to clarithromycin's broad effectiveness against respiratory tract pathogens.
Clarithromycin Krka is approved for the treatment of the following bacterial infections in adults and children aged 12 years and older:
- Lower respiratory tract infections: Including acute bacterial bronchitis and community-acquired pneumonia (CAP). Clarithromycin is effective against the most common causative organisms, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and atypical pathogens such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.
- Upper respiratory tract infections: Including acute bacterial sinusitis and pharyngitis/tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococcus). Clarithromycin is an important alternative for patients with penicillin allergy who require treatment for streptococcal pharyngitis.
- Skin and soft tissue infections: Including uncomplicated skin infections such as folliculitis, cellulitis, and erysipelas caused by susceptible organisms like Staphylococcus aureus and Streptococcus pyogenes.
- Helicobacter pylori eradication: In combination with proton pump inhibitors and other antibiotics (such as amoxicillin or metronidazole) for the treatment of duodenal ulcers associated with H. pylori infection. The Maastricht VI/Florence Consensus Report (2022) provides current international guidelines for H. pylori management, and clarithromycin-based triple therapy remains a first-line option in regions where clarithromycin resistance is below 15%.
Clarithromycin achieves tissue concentrations that are substantially higher than its plasma levels, particularly in respiratory tissues including bronchial mucosa, lung tissue, and alveolar macrophages. This property makes it particularly well-suited for treating respiratory tract infections. Additionally, clarithromycin has intracellular penetration capabilities, which are important for treating infections caused by intracellular pathogens such as Mycoplasma, Chlamydophila, and Legionella species.
Clarithromycin should only be used to treat bacterial infections as confirmed or strongly suspected by your healthcare provider. It does not work against viral infections such as the common cold or influenza. Using antibiotics when they are not needed contributes to antibiotic resistance, which the WHO has identified as one of the top 10 global public health threats. Always complete the full prescribed course and never share antibiotics with others.
What Should You Know Before Taking Clarithromycin Krka?
Before starting treatment with Clarithromycin Krka, it is essential that your prescribing physician has a complete picture of your medical history, current medications, and any known allergies. Clarithromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system, which means it can significantly affect the metabolism of many other drugs. Additionally, there are certain medical conditions that make clarithromycin unsuitable or require extra caution.
Contraindications
You must not take Clarithromycin Krka in any of the following circumstances:
- Allergy to macrolide antibiotics: If you are allergic to clarithromycin, erythromycin, azithromycin, or any other macrolide antibiotic, or to any of the inactive ingredients in the tablets.
- Ergot alkaloid use: If you take medications containing ergotamine or dihydroergotamine (used for migraine), or use ergotamine inhalers. The combination can cause dangerous vasoconstriction (ergotism).
- Certain statin use: If you take simvastatin or lovastatin, as the combination can cause severe muscle breakdown (rhabdomyolysis).
- Lomitapide: If you take lomitapide (used for high cholesterol).
- QT-prolonging medications: If you take terfenadine, astemizol, cisapride, domperidone, or pimozide, as the combination can cause serious, potentially fatal heart rhythm disturbances.
- Cardiac medications: If you take ticagrelor, ivabradine, or ranolazine.
- Colchicine: If you take colchicine (used for gout).
- Oral midazolam: If you take midazolam by mouth (a sedative).
- Low electrolytes: If you have abnormally low potassium (hypokalemia) or magnesium (hypomagnesemia) in your blood.
- QT prolongation or arrhythmias: If you or a family member have a history of QT prolongation on ECG or ventricular arrhythmias, including torsades de pointes.
- Severe liver or kidney problems: If you have significant hepatic or renal impairment (your doctor will assess this).
Clarithromycin can prolong the QT interval on the electrocardiogram (ECG), potentially leading to dangerous heart rhythm disturbances including torsades de pointes and ventricular tachycardia. This risk is increased when combined with other drugs that prolong QT, in patients with existing heart conditions, and in those with low potassium or magnesium levels. If you experience palpitations, dizziness, or fainting while taking clarithromycin, seek immediate medical attention.
Warnings and Precautions
Tell your doctor before starting Clarithromycin Krka if any of the following apply to you:
- Heart problems: Any existing cardiovascular disease, including coronary artery disease, heart failure, or conduction abnormalities.
- Kidney problems: Impaired renal function may require dose adjustments, as clarithromycin and its active metabolite are partially excreted through the kidneys.
- Liver disease: Clarithromycin is extensively metabolized in the liver. Pre-existing hepatic impairment increases the risk of liver-related side effects.
If you develop severe or prolonged diarrhea during or after treatment with Clarithromycin Krka, contact your doctor immediately. This could be a symptom of Clostridioides difficile-associated diarrhea (CDAD), a potentially serious condition where the normal gut flora is disrupted, allowing overgrowth of the C. difficile bacterium. CDAD can range from mild diarrhea to life-threatening pseudomembranous colitis, and it can occur during treatment or even up to two months afterward.
If you develop symptoms of impaired liver function, such as loss of appetite, yellowing of the skin or whites of the eyes (jaundice), dark urine, itching, or abdominal tenderness, stop taking Clarithromycin Krka immediately and contact your doctor. Hepatotoxicity, including hepatocellular and cholestatic forms, has been reported with clarithromycin use, and in rare cases, hepatic failure with fatal outcome has occurred.
Prolonged or repeated use of Clarithromycin Krka may lead to superinfection with resistant bacteria or fungi. Your doctor will monitor you for this possibility, particularly during longer courses of treatment.
Pregnancy and Breastfeeding
The safety of clarithromycin during pregnancy has not been established in adequately controlled human studies. Animal reproduction studies have shown adverse effects on embryo-fetal development. Therefore, Clarithromycin Krka is generally not recommended during pregnancy unless the potential clinical benefit to the mother clearly outweighs the potential risk to the fetus. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, consult your doctor before taking this medication.
Clarithromycin and its active metabolite 14-hydroxyclarithromycin are excreted in human breast milk. While concentrations in breast milk are generally small, the potential for effects on the breastfed infant should be considered. Your doctor will help you weigh the benefits of breastfeeding against the potential risks of treatment to decide the best course of action.
Driving and Operating Machinery
Clarithromycin Krka may cause dizziness, vertigo, confusion, and disorientation in some patients. If you experience any of these effects, you should not drive vehicles or operate machinery until you know how the medication affects you. You are responsible for assessing your own fitness to drive or perform tasks requiring alertness.
Clarithromycin Krka contains less than 1 mmol (23 mg) of sodium per dose. It is essentially sodium-free and suitable for patients on a sodium-restricted diet.
How Does Clarithromycin Krka Interact with Other Drugs?
Clarithromycin is one of the most clinically significant inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme system. CYP3A4 is responsible for the metabolism of approximately 50% of all commonly prescribed medications. By inhibiting this enzyme, clarithromycin can significantly increase the blood levels of co-administered drugs that are CYP3A4 substrates, potentially leading to enhanced effects, toxicity, or dangerous adverse reactions. Additionally, clarithromycin is itself a substrate of CYP3A4, so drugs that induce or inhibit this enzyme can alter clarithromycin's own blood levels.
Clarithromycin also inhibits the P-glycoprotein (P-gp) drug transporter, which can further increase the absorption and decrease the elimination of certain drugs. This dual inhibition of CYP3A4 and P-gp makes clarithromycin's interaction profile particularly complex and clinically important.
Contraindicated Combinations (Must Not Be Used Together)
| Drug | Category | Risk |
|---|---|---|
| Ergotamine / Dihydroergotamine | Migraine treatment | Acute ergot toxicity with vasospasm, ischemia of the extremities |
| Simvastatin / Lovastatin | Cholesterol-lowering (statins) | Rhabdomyolysis (severe muscle breakdown potentially causing kidney failure) |
| Lomitapide | Cholesterol-lowering | Significantly increased lomitapide levels, hepatotoxicity risk |
| Terfenadine / Astemizole | Antihistamines | QT prolongation, torsades de pointes, cardiac arrest |
| Cisapride / Domperidone | GI motility agents | QT prolongation, serious cardiac arrhythmias |
| Pimozide | Antipsychotic | QT prolongation, torsades de pointes |
| Ticagrelor | Antiplatelet agent | Significantly increased ticagrelor levels, bleeding risk |
| Ivabradine / Ranolazine | Cardiovascular agents | QT prolongation, cardiac toxicity |
| Colchicine | Gout treatment | Life-threatening colchicine toxicity (multi-organ failure) |
| Midazolam (oral) | Sedative / Anxiolytic | Excessive sedation and respiratory depression |
Interactions Requiring Monitoring or Dose Adjustment
The following medications can be used with clarithromycin but require careful monitoring by your healthcare provider, potential dose adjustments, or additional blood tests:
| Drug | Category | Effect / Action Required |
|---|---|---|
| Warfarin and other anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) | Blood thinners | Increased anticoagulant effect; INR monitoring required for warfarin |
| Digoxin | Heart medication | Increased digoxin levels via P-gp inhibition; monitor serum digoxin and ECG |
| Quinidine / Disopyramide | Antiarrhythmics | Risk of QT prolongation; ECG and blood level monitoring |
| Theophylline | Bronchodilator (asthma) | Increased theophylline levels; monitor blood levels |
| Carbamazepine / Phenytoin / Valproate | Anti-epileptic drugs | Increased carbamazepine levels; drug level monitoring essential |
| Cyclosporine / Tacrolimus / Sirolimus | Immunosuppressants | Significantly increased immunosuppressant levels; monitor trough levels and renal function |
| Triazolam / Alprazolam / IV Midazolam | Benzodiazepines | Increased sedation; consider dose reduction |
| Verapamil / Amlodipine / Diltiazem | Calcium channel blockers | Risk of hypotension and bradycardia; blood pressure monitoring |
| Sildenafil / Tadalafil / Vardenafil | PDE5 inhibitors | Increased exposure; consider starting at lowest dose |
| Insulin / Repaglinide / Pioglitazon | Diabetes medications | Risk of hypoglycemia; monitor blood glucose closely |
| Rifampicin / Rifabutin | Anti-tuberculosis drugs | Decreased clarithromycin levels (CYP3A4 induction); reduced efficacy |
| Hydroxychloroquine / Chloroquine | Antimalarials / Rheumatology | Additive risk of QT prolongation and cardiac arrhythmias |
If you are taking oral contraceptives and experience diarrhea or vomiting while on clarithromycin, you should use an additional barrier method of contraception (such as a condom) as the effectiveness of hormonal contraception may be reduced.
St. John's Wort (Hypericum perforatum), phenobarbital, and other strong CYP3A4 inducers can significantly reduce clarithromycin blood levels, potentially leading to treatment failure and contributing to antibiotic resistance. Avoid using these substances during clarithromycin therapy.
What Is the Correct Dosage of Clarithromycin Krka?
Always take Clarithromycin Krka exactly as your doctor or pharmacist has told you. Do not change the dose or stop treatment without consulting your healthcare provider first. The tablets should be swallowed whole with at least half a glass of water. Clarithromycin Krka can be taken with or without food, although taking it with food may help reduce gastrointestinal side effects.
Adults and Children Over 12 Years
Standard Infections (Respiratory, Throat, Sinus, Skin)
The recommended dose is 250 mg twice daily (one 250 mg tablet in the morning and one in the early evening) for 6 to 14 days. Your doctor will determine the appropriate duration based on the type and severity of infection.
For more severe infections, the dose may be increased to 500 mg twice daily (one 500 mg tablet in the morning and one in the early evening).
Helicobacter pylori Eradication (Duodenal Ulcers)
Clarithromycin is used at 500 mg twice daily as part of a combination regimen. Several internationally recognized combination protocols exist:
- Clarithromycin 500 mg + Amoxicillin 1000 mg + Lansoprazole 30 mg — all twice daily for 7–14 days
- Clarithromycin 500 mg + Metronidazole 400 mg + Lansoprazole 30 mg — all twice daily for 7–14 days
- Clarithromycin 500 mg + Amoxicillin 1000 mg + Omeprazole 20–40 mg — clarithromycin and amoxicillin twice daily, omeprazole once daily for 7–14 days
Your doctor will prescribe the most appropriate combination for your situation.
Children Under 12 Years
Clarithromycin Krka 250 mg and 500 mg film-coated tablets are not suitable for children under 12 years of age. For younger children, doctors may prescribe alternative formulations of clarithromycin (such as oral suspension) or a different appropriate antibiotic. The dosing in younger children is typically weight-based and must be determined by the prescribing physician.
Elderly Patients
No specific dose adjustment is routinely required for elderly patients with normal kidney function. However, elderly individuals are more likely to have impaired renal function, existing cardiac conditions, and to be taking multiple medications that may interact with clarithromycin. Physicians should carefully assess renal function and review the patient's full medication list before prescribing. The dose may need to be reduced in elderly patients with significant kidney impairment.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Taking more tablets per day than prescribed by your doctor can increase the risk of side effects without improving treatment outcomes.
Overdose
If you take more Clarithromycin Krka than prescribed, or if a child accidentally ingests the medication, contact your doctor, hospital emergency department, or poison control center immediately. Overdose of clarithromycin is likely to cause gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. Treatment is supportive, with gastric decontamination and symptomatic management as appropriate. Clarithromycin is not effectively removed by hemodialysis or peritoneal dialysis.
It is crucial that you complete the full course of Clarithromycin Krka as prescribed by your doctor, even if you start feeling better before the treatment is finished. Stopping antibiotics early allows surviving bacteria, including those with partial resistance, to recover and multiply. This contributes to antibiotic resistance and increases the risk that your infection may return and be more difficult to treat.
What Are the Side Effects of Clarithromycin Krka?
Clinical trials and post-marketing surveillance have identified a range of side effects associated with clarithromycin use. The majority of side effects are mild to moderate in severity and resolve after the course of treatment is completed. However, some side effects can be serious and require immediate medical attention.
- Severe or bloody diarrhea (even up to two months after treatment)
- Skin rash, breathing difficulties, fainting, or swelling of face and throat (signs of severe allergic reaction / anaphylaxis)
- Yellowing of skin or eyes, dark urine, pale stools, abdominal tenderness (signs of liver problems)
- Severe skin reactions with blistering of skin, mouth, lips, eyes, and genitals (Stevens-Johnson syndrome / toxic epidermal necrolysis)
- Muscle pain, tenderness, or weakness (rhabdomyolysis)
Common Side Effects
- Insomnia (difficulty sleeping)
- Dysgeusia (altered taste sensation)
- Headache
- Nausea, vomiting, abdominal pain
- Dyspepsia (indigestion)
- Diarrhea
- Abnormal liver function test results
- Skin rash
- Excessive sweating (hyperhidrosis)
- Flushing
Uncommon Side Effects
- Skin or vaginal infections, oral thrush (candidiasis)
- Changes in white blood cell or platelet counts
- Allergic reactions
- Decreased appetite, anxiety, nervousness
- Dizziness, drowsiness, tremor, involuntary movements
- Vertigo, tinnitus (ringing in the ears), hearing loss
- Palpitations, altered heart rhythm, cardiac arrest
- Breathing difficulties (asthma), nosebleeds
- Constipation, flatulence, acid reflux, bloating
- Inflammation of stomach lining, esophagus, or tongue
- Dry mouth, oral soreness
- Hepatitis, cholestasis (bile flow obstruction)
- Urticaria (hives), pruritus (itching), skin inflammation
- Muscle stiffness, pain, or spasms
- Kidney function changes
- Fever, chills, fatigue, chest pain
Not Known (Frequency Cannot Be Estimated)
- Clostridioides difficile colitis
- Psychotic disorder, confusion, hallucinations, depression
- Disorientation, abnormal dreams, manic episodes
- Seizures (convulsions)
- Loss or changes in taste and/or smell (ageusia, anosmia)
- Paraesthesia (tingling, numbness), peripheral neuropathy
- Deafness
- Torsades de pointes, ventricular tachycardia
- Hemorrhage
- Pancreatitis (inflammation of the pancreas)
- Tooth and tongue discoloration
- Liver failure, cholestatic jaundice
- DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)
- Acute generalized exanthematous pustulosis (AGEP)
- Stevens-Johnson syndrome / toxic epidermal necrolysis
- Acne
- Myopathy (muscle disease)
- Interstitial nephritis, renal failure
If you experience any side effects not listed here, or if any of the listed side effects become severe, please consult your doctor or pharmacist. Reporting suspected adverse reactions after authorization of the medicinal product is important for ongoing safety monitoring. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority.
Altered taste (dysgeusia) is one of the most characteristic side effects of clarithromycin, often described as a metallic or bitter taste in the mouth. This typically occurs within the first few days of treatment and usually resolves within one to two weeks after completing the antibiotic course. Drinking water, sucking on sugar-free sweets, or maintaining good oral hygiene can help manage this side effect.
How Should You Store Clarithromycin Krka?
Proper storage of medications is essential to maintain their safety and effectiveness throughout the shelf life. Clarithromycin Krka film-coated tablets do not require any special storage conditions, which makes them relatively easy to store in a standard home environment. However, several important guidelines should be followed:
- Keep out of the sight and reach of children. Store the medicine in a secure location where children cannot access it. Accidental ingestion of antibiotics by children can be harmful.
- Check the expiry date. Do not use Clarithromycin Krka after the expiry date stated on the packaging after "EXP." The expiry date refers to the last day of that month.
- Store in original packaging. Keep the tablets in their blister pack to protect them from moisture and light until you are ready to take them.
- Proper disposal. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer need. These measures help to protect the environment, as active pharmaceutical ingredients can contaminate water sources and soil.
If you notice any visible changes to the tablets, such as discoloration, crumbling, or an unusual odor, do not take them and consult your pharmacist for a replacement.
What Does Clarithromycin Krka Contain?
Understanding the full composition of a medication is important, particularly for patients with known allergies or sensitivities to specific excipients (inactive ingredients). Clarithromycin Krka tablets contain the following components:
Active Substance
- Clarithromycin 250 mg: Each film-coated tablet contains 250 mg of clarithromycin.
- Clarithromycin 500 mg: Each film-coated tablet contains 500 mg of clarithromycin.
Inactive Ingredients (Excipients)
Tablet core: Microcrystalline cellulose, croscarmellose sodium, povidone K30, colloidal anhydrous silica, magnesium stearate, talc, and stearic acid.
Film coating: Titanium dioxide (E171), hypromellose, hydroxypropylcellulose, yellow iron oxide (E172), and propylene glycol.
Appearance and Packaging
The 250 mg tablets are oval, biconvex, slightly brownish-yellow film-coated tablets measuring approximately 15–15.2 mm in length and 8 mm in width. The 500 mg tablets are also oval, biconvex, slightly brownish-yellow film-coated tablets measuring approximately 19.5–19.8 mm in length and 10 mm in width.
Clarithromycin Krka 250 mg is available in blister packs of 10, 12, 14, 16, or 20 film-coated tablets. Clarithromycin Krka 500 mg is available in blister packs of 7, 10, 14, 16, 20, or 21 film-coated tablets. Not all pack sizes may be marketed in every country.
The marketing authorization holder is KRKA, d.d., Novo mesto, Slovenia, and it is manufactured at KRKA's facilities in Novo mesto, Slovenia, and by TAD Pharma GmbH in Cuxhaven, Germany.
Frequently Asked Questions About Clarithromycin Krka
Clarithromycin Krka is a macrolide antibiotic prescribed for bacterial infections in adults and children aged 12 years and older. It treats respiratory tract infections (bronchitis, community-acquired pneumonia), throat and sinus infections (pharyngitis, sinusitis), skin and soft tissue infections, and is used in combination therapy to eradicate Helicobacter pylori in patients with duodenal ulcers. It is effective against a wide range of bacteria including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and atypical pathogens such as Mycoplasma pneumoniae and Legionella species.
There is no absolute contraindication to drinking alcohol while taking clarithromycin. However, it is generally advisable to limit or avoid alcohol consumption during any antibiotic treatment. Both clarithromycin and alcohol are metabolized by the liver, and combining them may increase the risk of gastrointestinal side effects such as nausea and upset stomach. Alcohol can also impair immune function and slow recovery from infections. If you have liver problems, you should avoid alcohol entirely while on clarithromycin.
Clarithromycin begins working as soon as it reaches therapeutic concentrations in the body, typically within the first 2–3 hours after the first dose. However, you may not feel better immediately. Most patients start noticing improvement in their symptoms within 2 to 3 days of starting treatment. If your symptoms have not improved after 3–5 days, or if they worsen at any point, contact your doctor. It is important to complete the full prescribed course even after you begin to feel better.
Both clarithromycin and azithromycin are macrolide antibiotics with similar spectra of activity, but they differ in several important ways. Clarithromycin is taken twice daily and typically for 6–14 days, while azithromycin is usually taken once daily for 3–5 days. Clarithromycin is a more potent CYP3A4 inhibitor and has more drug interactions. Clarithromycin produces an active metabolite (14-hydroxyclarithromycin) that enhances its activity against certain pathogens. Azithromycin has a longer tissue half-life and fewer drug interactions but may carry a slightly different cardiac risk profile. Your doctor will choose the most appropriate macrolide based on the specific infection, your other medications, and medical history.
Yes, clarithromycin can affect the heart by prolonging the QT interval on the electrocardiogram (ECG). In rare cases, this can lead to serious cardiac arrhythmias, including torsades de pointes and ventricular tachycardia. The risk is higher in patients who already have heart conditions, those taking other QT-prolonging medications, patients with low potassium or magnesium levels, and elderly patients. FDA safety reviews have also investigated a potential association between clarithromycin and long-term cardiovascular events. Patients with known cardiac disease should discuss the risks and benefits with their doctor before starting treatment.
The safety of clarithromycin during pregnancy has not been established. Animal studies have shown potential for adverse effects on fetal development, and it is generally not recommended during pregnancy unless the benefit clearly outweighs the risk. Alternative antibiotics with better-established safety profiles during pregnancy, such as amoxicillin or certain cephalosporins, may be preferred. Clarithromycin is excreted in breast milk in small amounts. Breastfeeding mothers should discuss the risks and benefits with their healthcare provider.
References
- European Medicines Agency (EMA). Clarithromycin – Summary of Product Characteristics. Last updated 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list, 2023. Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Clarithromycin. National Institute for Health and Care Excellence (NICE). Updated 2025.
- Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762. doi:10.1136/gutjnl-2022-327745
- U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease. 2018.
- Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am. 2004;18(3):621–649. doi:10.1016/j.idc.2004.04.010
- Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999;37(5):385–398. doi:10.2165/00003088-199937050-00003
- Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992;11(2):137–152.
- National Institute for Health and Care Excellence (NICE). Antimicrobial prescribing guidelines. Updated 2025.
- European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe. Annual report, 2024.
About the Medical Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – specialists in infectious disease and clinical pharmacology
Medical Review
Reviewed by iMedic Medical Review Board according to WHO, EMA, FDA, and NICE guidelines
Evidence Standard
Level 1A – Systematic reviews and meta-analyses of randomized controlled trials (GRADE framework)
Independence
No pharmaceutical company funding or sponsorship. Independent medical editorial content
Last medically reviewed: | Published: